Next Article in Journal
Novel Chitin Deacetylase from Thalassiosira weissflogii Highlights the Potential for Chitin Derivative Production
Previous Article in Journal
Genetic Markers of Insulin Resistance and Atherosclerosis in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Metabolites
Volume 13
Issue 3
10.3390/metabo13030428
metabolites-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Metabolomic Changes in Patients Affected by Multiple Sclerosis and Treated with Fingolimod

by
Federica Murgia
1,†,
Lorena Lorefice
2,†,
Antonio Noto
1,
Martina Spada
1,
Jessica Frau
2,
Giuseppe Fenu
2,
Giancarlo Coghe
2,
Antonella Gagliano
3,
Luigi Atzori
1,*,‡ and
Eleonora Cocco
4,‡
1
Department of Biomedical Sciences, Clinical Metabolomics Unit, University of Cagliari, 09124 Cagliari, Italy
2
Department of Medical Science and Public Health, University of Cagliari, 09124 Cagliari, Italy
3
Department of Health Science, “Magna Graecia” University of Catanzaro, 88100 Catanzaro, Italy
4
Multiple Sclerosis Center, Binaghi Hospital, ASSL Cagliari, 09126 Cagliari, Italy
*
Author to whom correspondence should be addressed.
†
Equally contributing first authors.
‡
Equally contributing last authors.
Metabolites 2023, 13(3), 428; https://doi.org/10.3390/metabo13030428
Submission received: 13 February 2023 / Revised: 28 February 2023 / Accepted: 3 March 2023 / Published: 15 March 2023
(This article belongs to the Section Advances in Metabolomics)
Browse Figures
Versions Notes

Abstract

:
Current treatment for Multiple Sclerosis (MS) consists of a multidisciplinary approach including disease-modifying therapies. The response to treatment is heterogeneous, representing a crucial challenge in the classification of patients. Metabolomics is an innovative tool that can identifies biomarkers/predictors of treatment response. We aimed to evaluate plasma metabolic changes in a group of naïve Relapsing-Remitting MS patients starting Fingolimod treatment, to find specific metabolomic features that predict the therapeutic response as well as the possible side effects. The study included 42 Relapsing-Remitting MS blood samples, of which 30 were classified as responders after two years of FINGO treatment, whereas 12 patients were Not-Responders. For fifteen patients, samples were collected at four time points: before starting the therapy; at six months after the initiation; at twelve months after; and at twenty-four months after initiation. The serum was analysed through Nuclear Magnetic Resonance and multivariate and univariate statistical analysis. Considering the single comparison between each time point, it was possible to identify a set of metabolites changing their concentrations based on the drug intake. FINGO influences aminoacidic and energy metabolisms and reduces oxidative stress and the activity of the immune system, both typical features of MS.

Graphical Abstract

1. Introduction

Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) that results from immune-mediated inflammation, demyelination, and axonal damage, characterized by dysfunctions in multiple CNS functions. The total number of people living with MS worldwide is estimated to be 2.5 million. It affects mainly young females with a rate of 3:1, with onset ranging from 20–50 years [1]. The aetiology of MS is still not completely understood, and several causes are responsible for this multifactorial disease [2]. Furthermore, MS shows a particularly complex pathophysiology that hinders the identification of effective therapy, which may have several significant side effects [3]. Current treatment for MS consists of a multidisciplinary approach including disease-modifying therapies (DMTs) which, by acting mainly on the inflammatory processes underlying MS, decrease the frequency of relapses and reduce short-term disability [4]. However, the response to treatment is quite heterogeneous because many patients continue to experience MS disease activity [5]. These aspects represent a crucial challenge in managing MS and highlight the need to identify biomarkers that allow the classification of patients based on their potential responsiveness to different drugs and risk of severe adverse events [6,7].
Fingolimod (FINGO) (Gilenya; 1.25 mg) is an oral drug approved for relapsing-remitting (RR) MS by the FDA in 2010 as a first-line treatment, and by the EMA in 2011 as a second-line treatment. FINGO modulates sphingosine-1-phosphate (S1P) receptors, inducing inhibition of the egress of T cells and B cells from lymph nodes into blood, and thus their traffic into the CNS, with favorable effects on MS inflammatory damage. Several trials and real-world studies have been conducted, indicating the efficacy/effectiveness of FINGO on MS activity as well as on disease progression in adult and pediatric MS patients [8,9,10]. After the first dose, rare transient FINGO-associated bradycardia, and heart conduction abnormalities, usually asymptomatic, have been reported. While there is a risk of infections during treatment, even if severe, opportunistic infections are rarely observed.
However, the most important challenge in clinical practice is to identify the best patient candidate for each disease-modifying treatment (DMT), as well as predictors of a better response to the drug. Recently, the metabolomic approach has emerged as an innovative and effective tool that, through a non-invasive analysis, allows for describing the phenotype of patients, recognizing metabolic patterns that are disease-related, and identify biomarkers as predictors of treatment response. Based on these considerations, the present study aimed to evaluate the plasma metabolic modifications in a group of naïve RRMS patients starting FINGO, also analysing whether specific metabolomic characteristics present at baseline could predict the FINGO therapeutic response as well as the possible side effects.

2. Materials and Methods

2.1. Patients

The study included a group of RRMS patients (diagnosed according to the McDonald 2010 criteria) who had been therapy-free for at least 90 days, to be initiated on therapy with FINGO, and a healthy control group. The blood samples of MS patients, drawn in the morning after overnight fasting, were collected at four time points: (1) before starting the therapy with FINGO—Time 0 (T0); (2) six months after FINGO initiation—Time 6 (T6); (3) twelve months after FINGO initiation—Time 12 (T12); and twenty-four months after FINGO—Time 24 (T24). The patients’ clinical features (disease duration and level of disability evaluated using the Expanded Disability Status Scale (EDSS) and MRI data (presence of Gd-enhancing lesions)) were recorded prior to FINGO initiation, whereas the number of clinical relapses, EDSS variations, and the presence of new/enlarging T2 or T1 Gd-enhancing lesions on MRI were collected at T12 and T24.
Patients were categorized at T24 in two groups: responders (R) and no responders (NR), according to the NEDA 3 definition (absence of clinical relapses, no EDSS confirmed disability progression sustained for 6 months, and no new/enlarging T2 or T1 Gd-enhancing lesions on MRI). Metabolomic profiles at baseline and during treatment were compared.
The local institutional Ethics Committee approved the study and written informed consent was obtained from each participant.

2.2. Sample Preparation

Ten mL of blood were collected from each sample, and the plasma samples were stored at −80 °C until analysis. The plasma samples were extracted as previously described [11,12]. The hydrophilic phase was concentrated overnight using a speed vacuum centrifuge for the subsequent 1H-NMR analysis.

2.3. H-NMR Analysis and Data Processing

Seven hundred microliters of the water-phase of each sample were concentrated overnight in a speed-vacuum. Then, it was resuspended in 690 µL of phosphate buffer pH = 7.0 in D2O and 10 µL trimethylsilyl propanoic acid (TSP) 5.07 mM. Samples were analysed as previously described [12].
The obtained spectra were manually phased and baseline corrected. To minimize the effects of the different concentrations of serum samples, the integrated area within each bin was normalized to a constant sum of 100. The final data set consisted of a 146 × 82 matrix. The columns represent the normalized area of each bin (variables), and the rows represent the samples (subjects).

2.4. Statistical Analysis

A multivariate statistical analysis was performed using SIMCA-P software (ver. 16.0, Umetrics, Sweden) [13]. The variables were Pareto scaled. The initial data analyses were conducted using the Principal Component Analysis (PCA), which is important for exploring the sample distributions without classification. The DmodX and Hotelling’s T2 tests were applied to identify potential outliers. To evaluate a possible linear relationship between a matrix Y (dependent variables, for example, increasing therapy time) and a matrix X (predictor variables, e.g., metabolites) Partial Least Squares projection to latent structures regression (PLS) model was performed [14]. Orthogonal Partial Least Square (OPLS-DA) was subsequently applied to compare the different time point classes [15]. The variance and the predictive ability (R2X, R2Y, Q2) were established to evaluate the suitability of the models. OPLS-DA models were performed using only bins corresponding to VIP (Variable Influence on Projection) value > 1. Terms with VIP larger than 1 are the most relevant for explaining Y (assignment of two classes) [16]. In addition, a permutation test (n = 400) was performed to validate the models [16]. Finally, the scores from each OPLS-DA model were subjected to a CV-ANOVA to test for significance (p < 0.05). The S-plot extracted the most significant variables from each model, and the 1H-NMR data were identified using the Chenomx NMR Suite 7.1 (Chenomx Inc., Edmonton, AB, Canada) [17].
GraphPad Prism software (version 7.01, GraphPad Software, Inc., San Diego, CA, USA) was used to perform the univariate statistical analysis of the data. To verify the significance of the metabolites resulting from multivariate statistical analysis, two tests were used: (1) Wilcoxon test, and (2) U-Mann Whitney test.

3. Results

The study included 42 RRMS patients (54.8% female), of which 30 (71.43%) were classified as R after two years of FINGO treatment, whereas 12 patients were NR. Blood samples collected at all 4 timepoints were available for 15 patients; thus, only these patients were used to analyze the metabolic variation during the FINGO treatment. Twenty-two control subjects were also included in the study. The summary of the demographic is reported in Table 1. Samples were analysed through the 1H-NMR, and forty-four hydrophilic compounds were correctly identified.
The non-supervised multivariate PCA was firstly applied using the bins dataset to examine clustering or separation trends between samples and find potential outliers. The obtained score plots and the result of the T2 Hotelling test did not indicate the presence of outliers.
A longitudinal grouping of the samples was observed based on the period of the therapy intake and was subsequently observed by the application of the supervised model OPLS-DA.
Firstly, a supervised model was built considering all the samples, and Figure 1A shows a clear distribution of the samples based on the different time points (T0, T6, T12, T24). Furthermore, the close correlation between changes in metabolic profile and the FINGO treatment period (considered as months) is represented also in Figure 1B, where an R2 = 0.65 was achieved when a PLS model was performed.
Subsequently, to better explore metabolic changes that occurred during the two years of FINGO exposure, supervised single models were built comparing T0 with T6, with T12, and with T24. Figure 2 shows the results of the single comparisons between the classes.
The statistical parameters (R2X, R2Y, Q2, p-value, and data relative to the permutation tests) of the models were reported in Table 2. By analysing the VIPs list and the S-plot relative to each model, it was possible to identify a set of metabolites changing their concentrations based on the drug intake.
In Figure 3 the concentrations’ graphs, where almost one comparison showed a p-value < 0.05, are represented. The amino acids, alanine, phenylalanine, glycine, pyroglutamic acid, and tryptophan showed a linear increase during the two years of treatment with FINGO. The same trend was also observed for fructose, glucose, 2-hydroxisovalerate and creatinine, whereas lactate, isoleucine, and glutamate showed a decreased trend during the two years of treatment.
Figure 4 shows an OPLS-DA model with three classes, including each patient’s T0, T24 and the controls’ samples. This model demonstrated that the metabolomic profile of patients treated for 24 months is different from the basal profile and more similar to the control one (R2X = 0.44, R2Y = 0.67, Q2 = 0. 49, p < 0.001), although constituting a distinct class as shown in the scores plot of the model.
Moreover, the supervised OPLS-DA model (Figure 5A, R2X = 0.6, R2Y = 0.7, Q2 = 0.493, p = 0.002) shows the comparison between not-responders (NR) and responders (R) patients (according to NEDA 3 definition) considering only the T0 samples (Table 3). The model was validated through the respective permutation test (Figure 5B), and the most important variables were identified by analysing the V-plot and using the corresponding VIP value. Variables with a value > 1 were considered the most relevant (Figure 5C). The R group was characterized by an increased concentration of lactate and lysine, while the NR group showed a high glucose level.
Finally, a supervised model was built between patients who showed cardiac-adverse events after the FINGO treatment (n = 3) and patients who did not show any cardiac-adverse events. For this aim, only the T0 samples were considered (Figure 6). The statistical parameters were R2X = 0.53, R2Y = 0.86, and Q2 = 0.49, but the p-value was not significant, probably due to the small size of the group.

4. Discussion

The active form of FINGO binds a G protein receptor subtype (S1P1), inducing the sequester of lymphocytes inside the lymphoid organs, strongly reducing the number of circulating CD4+ and CD8+ cells [18]. As a result, an effective reduction in inflammatory disease activity is observed. A recent Cochrane revision by La Mantia et al. performed on 3531 RRMS patients treated with FINGO indicated that 24 months of treatment had an increased probability of being relapse-free compared with 6 and 12 months [19]. Notably, the same revision also shows substantial variability in the response to the drug among RRMS patients.
Our first aim was to identify plasma metabolic modifications in a group of naïve RRMS patients starting FINGO treatment and monitored periodically (four time points) for two years. As expected, FINGO induced significant changes in the patients’ metabolomic profile related with the time of the drug exposure (see Figure 1). Intriguingly, considering this metabolic shift observed during the treatment, the T24 time point resulted in being almost similar to the metabolomic profile identified in the healthy control group, which can be interpreted as an indicator of a reapproaching to health’s normality (Figure 2 and Figure 3). This is suggested by the series of OPLS-DA models shown in Figure 2, where naïve patients (T0) are compared at 6, 12, and 24 months. As hypothesized below, the resulting metabolic phenotype identified indicates a shared pattern of metabolites characterized by two main modifications: (1) the reduction in the inflammatory process, and (2) the reduction in oxidative stress, both typical features in RRMS patients.
According to the recent literature, the AAs metabolism is highly involved in MS patients [20,21]. MS is a chronic inflammatory demyelinating disease mediated by Th1, Th17, and B cell activities that need continuous access to AAs to maintain basal metabolism. Considering the time points from T0 to T24, RRMS patients showed different AA trends during the treatment.
Circulating branched-chain AAs, valine, and isoleucine levels were gradually reduced in RRMS patients compared with the controls (see Figure 3). By contrast, plasma leucine incremented after six months and remained stable until the end of the two years of therapy. Thus, reduced plasma valine and isoleucine levels could indicate a weakened T cell activity and a process of restoring immune homeostasis [22].
An indication of reduction in inflammation is indicated by the gradual increase in plasma glycine at T6 while reaching a steady state during the rest of the two years of therapy. Glycine is the major inhibitory neurotransmitter in the brain and shows anti-inflammatory properties by a systemic modulation of immune cell functions [23]. The increase in glycine concentration may be linked to a glutamate level, which could influence the release of inhibitory amino acids from neurons and astrocytes to maintain neural homeostasis [24]. Indeed, plasma glutamate concentration significantly decreased in treated RRMS patients. Glutamate is a critical mediator of brain function, and its excess can cause damage to the neurological tissue due to overstimulation of its receptors and subsequent excitotoxic injury of neurons, glial cells, and blood-brain barrier [25,26]. This is particularly important for MS patients, as demonstrated by Sarchielli et al., where either RRMS or secondary progressive MS patients displayed an increased concentration of glutamate in the CSF during relapse and a stable clinical phase [27]. Thus, the linear and significant decrease in RRMS patients treated with FINGO may indicate the restoration of the normal physiology of the blood-brain barrier and reduced damage to the CNS. In agreement with this hypothesis, recent works from Noda and Serpero demonstrated that patients treated with FINGO had a down-regulation of microglial production of the proinflammatory cytokines, such as tumor necrosis factor-alpha, interleukin-1, and interferon-gamma, which are known to induce hyperactivity of glutamatergic transmission [28,29,30,31,32,33].
A precursor of glutamate is pyroglutamic acid, which resulted in a significantly increased. It is formed through the cleavage by the 5-oxoprolinase in the γ-glutamyl cycle, in which glutathione is decomposed into γ-glutamyl amino and again converted to pyroglutamic acid through γ-glutamyl cyclotransferase [34]. Therefore, the increase in pyroglutamic acid may indicate the restoration of sera glutathione in RRMS patients associated with the pharmacological treatment, in turn counteracting the oxidative stress, a typical feature of the MS disease.
Plasma arginine concentration significantly increased during the FINGO treatment. As demonstrated by several studies, arginine metabolism results frequently altered in MS in both human and animal models [35,36,37]. The conversion of arginine to citrulline represents an important event in the chemical pathogenesis of the demyelinating disease. Therefore, in RRMS patients, a high concentration of plasma arginine achieved during the treatment may indicate a reduced conversion rate to citrulline, which, according to the neurodegenerative hypothesis, causes a destabilization of the membrane architecture and myelin degradation [38].
Tryptophan has also been shown to contribute to the disease progression of MS through the kynurenine pathway (KP) [39]. Considering all the time points, tryptophan was significantly increased, and a possible explanation regards the reducing activity of the KP. This finding is in line with our previous study, where we evaluated the effect of the treatment with Interferon-β on RRMS patients. Moreover, tryptophan was one of the main metabolites differentiating MS patients and healthy controls, being significantly lower in patients [12].
A mechanistic explanation is that FINGO modulates cytokines (including IFN-γ and TNF-α), potent inducers of the first-rate limiting enzyme of the KP, indoleamine-2-3 dioxygenase (IDO), preventing the conversion in quinolinic acid. The latter is a strong N-methyl-D-aspartate (NMDA) receptor agonist that can over-activate NMDA receptors to increase intracellular Ca2+ levels, leading to oxidative stress and cell death through glutamatergic excitotoxicity [40,41]. Moreover, KP is also implicated in the regulatory function of the immune system [42]. IDO is present in various immune cells and can be induced by interferons and LPS [43]. The activation of IDO is an important regulator of immune activation, as it counteracts the proliferation of reactive lymphocytes [39].
Thus, RRMS patients treated for two years with FINGO by reaching the plasma tryptophan concentration of the control group may have reduced oxidative stress, cell death, and immune activity.
Plasma glucose and fructose was statistically increased from the naïve (T0) up to the T24 time point, reaching the level of the control group. In particular, glucose is the primary source of energy in the mammalian brain, where it is used in the form of ATP for neuronal and non-neuronal cell survival and the generation of neurotransmitters. Apart from survival, glucose is also a substrate consumed by immunity cells for sustaining inflammatory conditions [44]. A situation of chronic immune activation can exceed the physiological bioenergetics metabolism, consuming a considerable amount of energy (up to 2000-kJ/day and more) [45]. Therefore, lower glucose concentrations at T0 can be interpreted as being used for greater production of the proinflammatory cytokine, whereas its increase may indicate a reduction in inflammation due to FINGO treatment. A marker of impaired glucose regulation and oxidative stress is also indicated by a high level of 2-hydroxybutyrate at T0, which arises from lipid oxidation. Several studies suggested the correlation between 2-hydroxybutyrate and the pathogenesis of MS. However, RRMS patients treated with FINGO for two years showed a significant plasma reduction in 2-hydroxybutyrate, which indirectly indicates a reduction in oxidative stress [46].
The metabolites that have not particularly improved are creatine and creatine phosphate, which, compared to the T0, did not change their concentrations during the treatment. This probably indicates muscle weakness, a typical feature in MS patients.
In summary, considering the first aim of the analysis, it is possible to state that a characteristic profile of the patient affected by RRMS is identifiable at T0. Nevertheless, this metabolic phenotype undergoes a significant evolution due to pharmacological treatment, such that it significantly approaches the group of healthy controls [11].
Specific metabolomic characteristics present at baseline (T0) could predict the therapeutic response to FINGO. Indeed, the R group was characterized by an increased concentration of lactate and lysine, while the NR group showed a high glucose level. Lactate is the product of anaerobic glycolysis, and the increase in patients who will respond to the therapy may indicate the presence of an energy impairment. Conversely, NR showed a high concentration of glucose, which could indicate an impairment of glucose metabolism. In any case, these preliminary data must be verified in a more extensive series to confirm these metabolic hypotheses.
Finally, an explorative analysis was conducted between patients at the T0 who showed cardiac-side effects after the FINGO treatment and patients who did not show any cardiac-side effects. Regrettably, the mathematical model was not statistically significant, probably due to the small size of the cardiac-side effects group; therefore, we could not speculate about the possible predictive metabolic biomarkers of this adverse event.

5. Conclusions

Our results suggest that treatment with FINGO influences aminoacidic and energy metabolisms and reduces oxidative stress and the activity of the immune system, both typical features of MS. Interestingly, some baseline metabolites were indicative of a better response to treatment, indicating their possible role as surrogate biomarkers to predict the FINGO response.
The achieved results are in line with our previous studies where we found the same altered pattern of metabolites correlated with pathways involved essentially in energetic homeostasis and immuno-inflammation, such as the tryptophan metabolism (Table 4). In our studies, tryptophan played a pivotal role in the definition of the basal metabolic profile of MS patients compared to controls but also in the response to the Interferon-β therapy, where it showed the same trend found in this latter study here presented. This demonstrated that the possibility of deeply investigating the tryptophan metabolism could represent a potential future target to improve the management of MS patients, especially in terms of response to the therapy. Considering the complexity of MS management, especially from the pharmacological point of view, 1H-NMR spectroscopy-based metabolomic analysis of blood appears to be a promising, innovative, and non-invasive approach to contribute to predicting the response to MS therapies, with possibly important implications for future personalized therapeutic decision-making processes.

Author Contributions

E.C. and L.L. designed the study. F.M., A.N. and M.S. analysed experimental data. L.L., J.F., G.F. and G.C. obtained and analysed the clinical data. A.G., E.C. and L.A. evaluated and provided critical assessments to the data. F.M., A.N. and L.L. drafted the article under the supervision of E.C. and L.A. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the principles of good clinical practice. The institutional ethics committee of the University of Cagliari approved the study (n° 20/2015). Moreover, the study was conducted in accordance with the Declaration of Helsinky.

Informed Consent Statement

Written informed consent was obtained from each participant.

Data Availability Statement

Data is not publicly available due to privacy.

Acknowledgments

We are grateful to the patients and their families for participation in this research study.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Milo, R.; Miller, A. Revised diagnostic criteria of multiple sclerosis. Autoimmun. Rev. 2014, 13, 518–524. [Google Scholar] [CrossRef] [PubMed]
  2. Compston, A.; Coles, A. Multiple sclerosis. Lancet 2008, 372, 1502–1517. [Google Scholar] [CrossRef] [PubMed]
  3. Loma, I.; Heyman, R. Multiple sclerosis: Pathogenesis and treatment. Curr. Neuropharmacol. 2011, 9, 409–416. [Google Scholar] [CrossRef] [PubMed]
  4. McGinley, M.P.; Goldschmidt, C.H.; Rae-Grant, A.D. Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA 2021, 325, 765–779. [Google Scholar] [CrossRef]
  5. Tedeschi, G.; Gallo, A. Multiple sclerosis patients and immunomodulation therapies: The potential role of new MRI techniques to assess responders versus non-responders. Neurol. Sci. 2005, 26, s209–s212. [Google Scholar] [CrossRef] [PubMed]
  6. Ziemssen, T.; Akgün, K.; Brück, W. Molecular biomarkers in multiple sclerosis. J. Neuroinflamm. 2019, 16, 272. [Google Scholar] [CrossRef]
  7. Harris, V.K.; Sadiq, S.A. Biomarkers of therapeutic response in multiple sclerosis: Current status. Mol. Diagn. Ther. 2014, 18, 605–617. [Google Scholar] [CrossRef]
  8. Kappos, L.; Radue, E.W.; O’Connor, P.; Polman, C.; Hohlfeld, R.; Calabresi, P.; Selmaj, K.; Agoropoulou, C.; Leyk, M.; Zhang-Auberson, L.; et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362, 387–401. [Google Scholar] [CrossRef]
  9. Cohen, J.A.; Barkhof, F.; Comi, G.; Hartung, H.P.; Khatri, B.O.; Montalban, X.; Pelletier, J.; Capra, R.; Gallo, P.; Izquierdo, G.; et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362, 402–415. [Google Scholar] [CrossRef]
  10. Fonseca, J. Fingolimod Real World Experience: Efficacy and Safety in Clinical Practice. Neurosci. J. 2015, 2015, 389360. [Google Scholar] [CrossRef]
  11. Cocco, E.; Murgia, F.; Lorefice, L.; Barberini, L.; Poddighe, S.; Frau, J.; Fenu, G.; Coghe, G.; Murru, M.R.; Murru, R.; et al. 1H-NMR analysis provides a metabolomic profile of patients with multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 2015, 3, e185. [Google Scholar] [CrossRef]
  12. Lorefice, L.; Murgia, F.; Fenu, G.; Frau, J.; Coghe, G.; Murru, M.R.; Tranquilli, S.; Visconti, A.; Marrosu, M.G.; Atzori, L.; et al. Assessing the metabolomic profile of multiple sclerosis patients treated with interferon beta 1a by 1H-NMR spectroscopy. Neurother. J. 2019, 16, 797–807. [Google Scholar] [CrossRef] [PubMed]
  13. Eriksson, L.; Byrne, T.; Johansson, E.; Trygg, J.; Vikstrom, C. Multi- and Megavariate Data Analysis Basic Principles and Applications, 3rd ed.; MKS Umetrics AB: Umea, Sweden, 2013; Volume 1. [Google Scholar]
  14. Wold, S.; Sjöström, M.; Eriksson, L. PLS-regression: A basic tool of chemometrics. Chemom. Intell. Lab. Syst. 2001, 58, 109–130. [Google Scholar] [CrossRef]
  15. Trygg, J.; Holmes, E.; Lundstedt, T. Chemometrics in metabonomics. J. Proteome Res. 2007, 6, 469–479. [Google Scholar] [CrossRef] [PubMed]
  16. Lindgren, F.; Hansen, B.; Karcher, W.; Sjöström, M.; Eriksson, L. Model validation by permutation tests: Applications to variable selection. J. Chemom. 1996, 10, 521–532. [Google Scholar] [CrossRef]
  17. Weljie, A.M.; Newton, J.; Mercier, P.; Carlson, E.; Slupsky, C.M. Targeted profiling: Quantitative analysis of 1H NMR metabolomics data. Anal. Chem. 2006, 78, 4430–4442. [Google Scholar] [CrossRef] [PubMed]
  18. Ingwersen, J.; Aktas, O.; Kuery, P.; Kieseier, B.; Boyko, A.; Hartung, H.P. Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy. Clin. Immunol. 2012, 142, 15–24. [Google Scholar] [CrossRef]
  19. La Mantia, L.; Tramacere, I.; Firwana, B.; Pacchetti, I.; Palumbo, R.; Filippini, G. Fingolimod for relapsing-remitting multiple sclerosis. Cochrane Database Syst. Rev. 2016, 4, CD009371. [Google Scholar] [CrossRef]
  20. Correale, J. Immunosuppressive Amino-Acid Catabolizing Enzymes in Multiple Sclerosis. Front. Immunol. 2021, 11, 600428. [Google Scholar] [CrossRef]
  21. Negrotto, L.; Correale, J. Amino Acid Catabolism in Multiple Sclerosis Affects Immune Homeostasis. J. Immunol. 2017, 198, 1900–1909. [Google Scholar] [CrossRef]
  22. Fitzgerald, K.C.; Smith, M.D.; Kim, S.; Sotirchis, E.S.; Kornberg, M.D.; Douglas, M.; Nourbakhsh, B.; Graves, J.; Rattan, R.; Poisson, L.; et al. Multi-omic evaluation of metabolic alterations in multiple sclerosis identifies shifts in aromatic amino acid metabolism. Cell Rep. Med. 2021, 2, 100424. [Google Scholar] [CrossRef]
  23. Carmans, S.; Hendriks, J.J.; Thewissen, K.; Van den Eynden, J.; Stinissen, P.; Rigo, J.M.; Hellings, N. The inhibitory neurotransmitter glycine modulates macrophage activity by activation of neutral amino acid transporters. J. Neurosci. Res. 2010, 88, 2420–2430. [Google Scholar] [CrossRef]
  24. Ďurfinová, M.; Bartová, R.; Orešanská, K.; Turecký, L.; Procházková, L.; Petrleničová, D.; Líška, B. Increased glycine levels in cerebrospinal fluid of patients with multiple sclerosis. Clin. Chim. Acta 2018, 486, 86–87. [Google Scholar] [CrossRef] [PubMed]
  25. Groom, A.J.; Smith, T.; Turski, L. Multiple sclerosis and glutamate. Ann. N. Y. Acad. Sci. 2003, 993, 229–275. [Google Scholar] [CrossRef] [PubMed]
  26. Pitt, D.; Nagelmeier, I.E.; Wilson, H.C.; Raine, C.S. Glutamate uptake by oligodendrocytes: Implications for excitotoxicity in multiple sclerosis. Neurology 2003, 61, 1113–1120. [Google Scholar] [CrossRef]
  27. Sarchielli, P.; Greco, L.; Floridi, A.; Floridi, A.; Gallai, V. Excitatory amino acids and multiple sclerosis: Evidence from cerebrospinal fluid. Arch. Neurol. 2003, 60, 1082–1088. [Google Scholar] [CrossRef]
  28. Noda, H.; Takeuchi, H.; Mizuno, T.; Suzumura, A. Fingolimod phosphate promotes the neuroprotective effects of microglia. J. Neuroimmunol. 2013, 256, 13–18. [Google Scholar] [CrossRef]
  29. Serpero, L.D.; Filaci, G.; Parodi, A.; Battaglia, F.; Kalli, F.; Brogi, D.; Mancardi, G.L.; Uccelli, A.; Fenoglio, D. Fingolimod modulates peripheral effector and regulatory T cells in MS patients. J. Neuroimmune Pharmacol. 2013, 8, 1106–1113. [Google Scholar] [CrossRef] [PubMed]
  30. Centonze, D.; Muzio, L.; Rossi, S.; Furlan, R.; Bernardi, G.; Martino, G. The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis. Cell Death Differ. 2010, 17, 1083–1091. [Google Scholar] [CrossRef] [PubMed]
  31. Groves, A.; Kihara, Y.; Chun, J. Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J. Neurol. Sci. 2013, 328, 9–18. [Google Scholar] [CrossRef]
  32. Pieragostino, D.; D’Alessandro, M.; di Ioia, M.; Rossi, C.; Zucchelli, M.; Urbani, A.; Di Ilio, C.; Lugaresi, A.; Sacchetta, P.; Del Boccio, P. An integrated metabolomics approach for the research of new cerebrospinal fluid biomarkers of multiple sclerosis. Mol. Biosyst. 2015, 11, 1563–1572. [Google Scholar] [CrossRef] [PubMed]
  33. Villoslada, P.; Alonso, C.; Agirrezabal, I.; Kotelnikova, E.; Zubizarreta, I.; Pulido-Valdeolivaset, I.; Saiz, A.; Comabella, M.; Montalban, X.; Villar, L.; et al. Metabolomic signatures associated with disease severity in multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 2017, 4, e321. [Google Scholar] [CrossRef] [PubMed]
  34. Bachhawat, A.K.; Yadav, S. The glutathione cycle: Glutathione metabolism beyond the γ-glutamyl cycle. IUBMB Life 2018, 70, 585–592. [Google Scholar] [CrossRef] [PubMed]
  35. Murgia, F.; Lorefice, L.; Poddighe, S.; Fenu, G.; Secci, M.A.; Marrosu, M.G.; Cocco, E.; Atzori, L. Multi-Platform Characterization of Cerebrospinal Fluid and Serum Metabolome of Patients Affected by Relapsing-Remitting and Primary Progressive Multiple Sclerosis. J. Clin. Med. 2020, 9, 863. [Google Scholar] [CrossRef]
  36. Stojanovic, I.; Vojinovic, S.; Ljubisavljevic, S.; Pavlovic, R.; Basic, J.; Pavlovic, D.; Ilic, A.; Cvetkovic, T.; Stukalov, M. INF-β1b therapy modulates L-arginine and nitric oxide metabolism in patients with relapse remittent multiple sclerosis. J. Neurol. Sci. 2012, 323, 187–192. [Google Scholar] [CrossRef]
  37. Mangalam, A.; Poisson, L.; Nemutlu, E.; Datta, I.; Denic, A.; Dzeja, P.; Rodriguez, M.; Rattan, R.; Giri, S. Profile of Circulatory Metabolites in a Relapsing-remitting Animal Model of Multiple Sclerosis using Global Metabolomics. J. Clin. Cell. Immunol. 2013, 4, 3. [Google Scholar] [CrossRef]
  38. Pritzker, L.B.; Joshi, S.; Gowan, J.J.; Harauz, G.; Moscarello, M.A. Deimination of myelin basic protein. 1. Effect of deimination of arginyl residues of myelin basic protein on its structure and susceptibility to digestion by cathepsin D. Biochemistry 2000, 39, 5374–5381. [Google Scholar] [CrossRef]
  39. Rajda, C.; Majláth, Z.; Pukoli, D.; Vécsei, L. Kynurenines and Multiple Sclerosis: The Dialogue between the Immune System and the Central Nervous System. Int. J. Mol. Sci. 2015, 16, 18270–18282. [Google Scholar] [CrossRef]
  40. Moroni, F.; Cozzi, A.; Sili, M.; Mannaioni, G. Kynurenic acid: A metabolite with multiple actions and multiple targets in brain and periphery. J. Neural. Transm. 2012, 119, 133–139. [Google Scholar] [CrossRef]
  41. Guillemin, G.J. Quinolinic acid, the inescapable neurotoxin. FEBS J. 2012, 279, 1356–1365. [Google Scholar] [CrossRef]
  42. Vécsei, L.; Szalárdy, L.; Fülöp, F.; Toldi, J. Kynurenines in the CNS: Recent advances and new questions. Nat. Rev. Drug Discov. 2013, 12, 64–82. [Google Scholar] [CrossRef]
  43. Mándi, Y.; Vécsei, L. The kynurenine system and immunoregulation. J. Neural. Transm. 2012, 119, 97–209. [Google Scholar] [CrossRef] [PubMed]
  44. Buttgereit, F.; Burmester, G.R.; Brand, M.D. Bioenergetics of immune functions: Fundamental and therapeutic aspects. Immunol. Today 2000, 21, 192–199. [Google Scholar] [CrossRef] [PubMed]
  45. Straub, R.H.; Cutolo, M.; Buttgereit, F.; Pongratz, G. Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J. Intern. Med. 2010, 267, 543–560. [Google Scholar] [CrossRef]
  46. Kim, H.H.; Jeong, I.H.; Hyun, J.S.; Kong, B.S.; Kim, H.J.; Park, S.J. Metabolomic profiling of CSF in multiple sclerosis and neuromyelitis optica spectrum disorder by nuclear magnetic resonance. PLoS ONE 2017, 12, e0181758. [Google Scholar] [CrossRef] [PubMed]
  47. Poddighe, S.; Murgia, F.; Lorefice, L.; Liggi, S.; Cocco, E.; Marrosu, M.G.; Atzori, L. Metabolomic analysis identifies altered metabolic pathways in Multiple Sclerosis. Int. J. Biochem. Cell. Biol. 2017, 93, 148–155. [Google Scholar] [CrossRef]
Metabolites 13 00428 g001 550
Figure 1. Multivariate models generated comparing all the groups of patients. Blood samples were collected at baseline (T0) and then at 6 (T6), 12 (T12), and 24 (T24) months of FINGO treatment. (A) OPLS-DA model including all the samples; (B) PLS correlation model generated using the x-variables (bins) and the y-variable as months of therapy (R2 = 0.65).
Figure 1. Multivariate models generated comparing all the groups of patients. Blood samples were collected at baseline (T0) and then at 6 (T6), 12 (T12), and 24 (T24) months of FINGO treatment. (A) OPLS-DA model including all the samples; (B) PLS correlation model generated using the x-variables (bins) and the y-variable as months of therapy (R2 = 0.65).
Metabolites 13 00428 g001
Metabolites 13 00428 g002 550
Figure 2. Supervised OPLS-DA models generated comparing the different classes of patients. Blood samples were collected at baseline (T0) and then after 6 (T6), 12 (T12), and 24 (T24) months of FINGO treatment. (A,B) OPLS-DA model between T0 and T6 and the respective permutation test. (C,D) OPLS-DA model between T0 and T12 and the respective permutation test. (E,F) OPLS-DA model between T0 and T24 and the respective permutation test.
Figure 2. Supervised OPLS-DA models generated comparing the different classes of patients. Blood samples were collected at baseline (T0) and then after 6 (T6), 12 (T12), and 24 (T24) months of FINGO treatment. (A,B) OPLS-DA model between T0 and T6 and the respective permutation test. (C,D) OPLS-DA model between T0 and T12 and the respective permutation test. (E,F) OPLS-DA model between T0 and T24 and the respective permutation test.
Metabolites 13 00428 g002
Metabolites 13 00428 g003 550
Figure 3. Most important metabolites identified by the analysis of the multivariate models (T0 vs. T6, T0 vs. T12, and T0 vs. T24) and the control group. Graphs indicating trend of the most important metabolites having p-value < 0.05 in at least one comparison of the different groups after the application of Wilcoxon test (T0 vs. T6, T12, T24) or U-Mann Whitney test (SM vs. C). * means p < 0.05, ** means p < 0.01, *** means p < 0.001. **** means p < 0.0001.
Figure 3. Most important metabolites identified by the analysis of the multivariate models (T0 vs. T6, T0 vs. T12, and T0 vs. T24) and the control group. Graphs indicating trend of the most important metabolites having p-value < 0.05 in at least one comparison of the different groups after the application of Wilcoxon test (T0 vs. T6, T12, T24) or U-Mann Whitney test (SM vs. C). * means p < 0.05, ** means p < 0.01, *** means p < 0.001. **** means p < 0.0001.
Metabolites 13 00428 g003
Metabolites 13 00428 g004 550
Figure 4. OPLS-DA model with 3 classes, including the T0 (grey circles) and T24 (violet circles) samples of each patient and the samples from healthy controls (black circles).
Figure 4. OPLS-DA model with 3 classes, including the T0 (grey circles) and T24 (violet circles) samples of each patient and the samples from healthy controls (black circles).
Metabolites 13 00428 g004
Metabolites 13 00428 g005 550
Figure 5. (A) OPLS-DA model obtained from 42 plasma samples of MS patients at time point T0. Patients were classified as responders (R) and non-responders (NR) after FINGO treatment, according to NEDA 3 definition. Statistical parameters were R2X  =  0.592, R2Y = 0.70, Q2 = 0.493, p = 0.002. (B) The model was validated through the respective permutation test. (C) Volcano plot indicating the most important variables responsible of the separation of the samples.
Figure 5. (A) OPLS-DA model obtained from 42 plasma samples of MS patients at time point T0. Patients were classified as responders (R) and non-responders (NR) after FINGO treatment, according to NEDA 3 definition. Statistical parameters were R2X  =  0.592, R2Y = 0.70, Q2 = 0.493, p = 0.002. (B) The model was validated through the respective permutation test. (C) Volcano plot indicating the most important variables responsible of the separation of the samples.
Metabolites 13 00428 g005
Metabolites 13 00428 g006 550
Figure 6. Supervised model of patients who showed cardiac-adverse events after the FINGO treatment and patients who did not show any cardiac-adverse events. The statistical parameters were R2X = 0.53, R2Y = 0.86, and Q2 = 0.49, but the p-value was not significant.
Figure 6. Supervised model of patients who showed cardiac-adverse events after the FINGO treatment and patients who did not show any cardiac-adverse events. The statistical parameters were R2X = 0.53, R2Y = 0.86, and Q2 = 0.49, but the p-value was not significant.
Metabolites 13 00428 g006
Table
Table 1. Demographic characteristics of MS patients and healthy controls.
Table 1. Demographic characteristics of MS patients and healthy controls.
Characteristics of Patients and Controls
MS patients
PatientsAge ± SD
Range		F/MMS duration (mean years)EDSS score
(mean)		Inclusion criteriaExclusion
criteria
42
SM-RR		39 ± 8.7
(22–56)		23/1910 ± 63 ± 1.7Adults ≥ 18 years of ageCorticosteroids exposure in the previous 30 days
MS diagnosis according to McDonald 2010 criteriaPresence of other chronic comorbidities
Relapsing remitting courseUse of other chronic medications
Scheduled Fingolimod treatment
Healthy controls
22
C		40.8 ± 13.8
(20–67)		17/5Adults ≥ 18 years of ageNo family history of MSPresence of chronic disease
Use of chronic medications
Table
Table 2. Summary of the statistical parameters of the multivariate models of the comparisons between the classes of subjects. Blood samples were collected at baseline (T0) and then at 6 (T6), 12 (T12), and 24 (T24) months of FINGO treatment.
Table 2. Summary of the statistical parameters of the multivariate models of the comparisons between the classes of subjects. Blood samples were collected at baseline (T0) and then at 6 (T6), 12 (T12), and 24 (T24) months of FINGO treatment.
SUPERVISED MODELS
NR2XR2YQ2p-ValuePermutation Test: Intercept R2/Q2
T0 vs. T6 vs. T12 vs. T24600.520.390.270.020.2/−0.33
T0 vs. T6 300.400.600.08ns0.38/−0.4
T0 vs. T12 300.420.760.52<0.0010.39/−0.55
T0 vs. T24300.510.900.72<0.00010.59/−0.7
T0 vs. T24 vs. C 520.440.670.49<0.00010.24/−0.35
R vs. NR420.600.700.490.0020.38/−0.6
Table
Table 3. Baseline characteristics of responder (R) and not-responder (NR) patients.
Table 3. Baseline characteristics of responder (R) and not-responder (NR) patients.
Baseline
Characteristics		R Patients
(n = 30)		NR Patients
(n = 12)
Age (mean) ± SD37 ± 8.643 ± 7.8
Gender F/M18/125/7
MS duration (mean years)913
EDSS score (mean)3 ± 1.83 ± 1.6
MRI activity (Gd + lesions)08 (67%)
Table
Table 4. Summary of the results of the studies performed by our research group.
Table 4. Summary of the results of the studies performed by our research group.
AuthorYearsSample
Size		BiofluidTechniqueResultsPathways
Basal metabolic profile
Cocco et al. [11]2015161 subjects:
73 MS
77 controls		Plasma1H-NMRIncrease: 3-OH-butyrate, acetoacetate, acetone, alanine, choline
Decrease: Glucose, 5-OH-tryptophan, tryptophan		Tryptophan metabolism
Energy metabolism
Poddighe et al. [47]201765 subjects:
32 MS
33 controls 		PlasmaGC-MSIncrease: asparagine, L-ornithine, glutamine, glutamate
Decrease: Fructose, myo-inositol, pyroglutamate, threonate, leucine 		Asparagine and Citrulline biosynthesis
Energy metabolism
MS subtypes
Murgia et al. [35]202034 subjects
22 RRMS
12 PPMS		CSF
Serum 		1H-NMR
GC-MS
L MS		Serum
Increase: PC aa C34:3, PC ae C38:1, PC ae C38:2, methionine-Sulfoxide
Decrease: PC aa C38:4, PC aa C40:5, SM C26:0, C5, alpha-aminoadipic acid, glutamate, valine, taurine, spermidine
CSF
Decrease: PCae C42:2, Ornithine
Increase: Histidine, Phenylalanine, Threonine		Serum
Glutathione metabolism, nitrogen metabolism, arginine and proline metabolism,
glutamine and glutamate metabolism,
linoleic acid metabolism, taurine and hypotaurine metabolism
alanine, aspartate, and glutamate metabolism.
CSF
Nitrogen metabolism, arginine and ornithine metabolism, branched chain amino acid (BCAAs) biosynthesis, phenylalanine, tyrosine and tryptophan biosynthesis and histidine metabolism.
Response to the IFN-β therapy
Lorefice et al. [12]201937 subjects:
21 MS
16 controls		Plasma1H-NMRDecrease: Acetoacetate, acetone, 3-hydroxybutyrate, glutamate, methylmalonate
Increase: Tryptophan		Energetic pathways Tryptophan metabolism
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Murgia, F.; Lorefice, L.; Noto, A.; Spada, M.; Frau, J.; Fenu, G.; Coghe, G.; Gagliano, A.; Atzori, L.; Cocco, E. Metabolomic Changes in Patients Affected by Multiple Sclerosis and Treated with Fingolimod. Metabolites 2023, 13, 428. https://doi.org/10.3390/metabo13030428

AMA Style

Murgia F, Lorefice L, Noto A, Spada M, Frau J, Fenu G, Coghe G, Gagliano A, Atzori L, Cocco E. Metabolomic Changes in Patients Affected by Multiple Sclerosis and Treated with Fingolimod. Metabolites. 2023; 13(3):428. https://doi.org/10.3390/metabo13030428

Chicago/Turabian Style

Murgia, Federica, Lorena Lorefice, Antonio Noto, Martina Spada, Jessica Frau, Giuseppe Fenu, Giancarlo Coghe, Antonella Gagliano, Luigi Atzori, and Eleonora Cocco. 2023. "Metabolomic Changes in Patients Affected by Multiple Sclerosis and Treated with Fingolimod" Metabolites 13, no. 3: 428. https://doi.org/10.3390/metabo13030428

APA Style

Murgia, F., Lorefice, L., Noto, A., Spada, M., Frau, J., Fenu, G., Coghe, G., Gagliano, A., Atzori, L., & Cocco, E. (2023). Metabolomic Changes in Patients Affected by Multiple Sclerosis and Treated with Fingolimod. Metabolites, 13(3), 428. https://doi.org/10.3390/metabo13030428

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop